期刊文献+

多黏菌素E联合比阿培南对耐碳青霉烯铜绿假单胞菌的体外抗菌活性研究 被引量:4

In vitro activity of colistin combination with biapenem against carbopenems-resistant Pseudomonas aeruginosa
原文传递
导出
摘要 目的评价多黏菌素E联合比阿培南对85株耐碳青霉烯铜绿假单胞菌(CRPA)的体外抗菌效应。方法用琼脂平板稀释法测定多黏菌素E和比阿培南对85株CRPA的最低抑菌浓度(MIC)值。用微量肉汤稀释法测定不同浓度组合的多黏菌素E和比阿培南对85株CRPA的MIC值,并计算部分抑菌浓度指数来判定联合效应。测定多黏菌素E与比阿培南单用或联用的时间杀菌曲线。结果多黏菌素E与比阿培南联合用药可显著降低CRPA的MIC(P<0.01)。多黏菌素E与比阿培南联合用药表现协同作用为11.76%、部分协同为17.65%、相加作用为34.12%、无关作用为36.47%、无拮抗作用。多黏菌素E联合比阿培南的细菌数量与单药相比降低>2 log_(10)CFU·mL^(-1)。结论多黏菌素E与比阿培南联合用药在体外对CRPA以协同作用和相加作用为主,杀菌曲线也显示了较好的协同作用。 Objective To evaluate the antibiotic effects of colistin conbined with biapenem against 85 isolates of Carbapenems- resistant Pseudomonas aeruginosa(CRPA) in vitro.Methods The minimal inhibitory concentration(MIC) of colistin or biapenem against 85 strains of CRPA was determined by agar dilution method.The broth microdilution and checkerboard method were used to determine the MICs of colistin or biapenem and fractional inhibitory concentration index(FICI) was calculated according to MIC results.The time- killing curves of colistin and biapenem alone or combination were determined.Results The MIC of all the combined antimicrobials was reduced significantly(P〈0.01).Of85 isolates,11.76%synergism,17.65%section synergism,34.12%additive effect,36.47%indifference,no antagonism found.At 24 h the combination resulted in more than 2 log_(10) CFU·mL^-1 reduction in viable bacteria compared with colistin or biapenem alone.Conclusion The activities of colistin combined with biapenem are mainly synergistic and additive.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2015年第24期2437-2439,共3页 The Chinese Journal of Clinical Pharmacology
基金 国家科技部十二五重大专项滚动课题项目(2012ZX09303004-002)
关键词 耐碳青霉烯铜绿假单胞菌 多黏菌素E 比阿培南 部分抑菌浓度 时间杀菌曲线 carbapenem-resistant Pseudomonas aeruginosa colistin biapenem fractional inhibitory concentration time-killing curve
  • 相关文献

参考文献5

  • 1施晓群,孙景勇,倪语星,汪复,朱德妹,胡付品,蒋晓飞,徐英春,张小江,胡云建,艾效曼,杨青,孙自镛,陈中举,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,王爱敏,张泓,孔菁,徐元宏,沈继录,单斌,杜艳,俞云松,林洁.2011年中国CHINET铜绿假单胞菌耐药性监测[J].中国感染与化疗杂志,2013,13(3):218-221. 被引量:98
  • 2Sahuquillo Arce JM, Colombo Gainza E, GilBrusola A, et al. In vitro activity of linezolid in combination with doxycycline, fosfomy- cin, levofloxacin, rifampicin and vancomycin against methicillin - susceptible staphylococcus aureus [ J]. Rev Esp Quimioter, 2006,19: 252- 257.
  • 3崔银珠.新型抗菌药物比阿培南(biapenem)[J].世界临床药物,2003,24(9):572-573. 被引量:10
  • 4汪雯,李玉,李陶,顾腾振.比阿培南联合舒巴坦对铜绿假单胞菌与鲍氏不动杆菌耐药性的影响[J].中华医院感染学杂志,2014,24(10):2407-2410. 被引量:7
  • 5Sheng WH, Wang JT, Li SY, et al. Comparative in vitro antimi- crobial susceptibilities and synergistic activities of antimicrobial combinations against Carbapenem - resistant Acinetobacter spe- cies: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU [ J]. Diagn Microbiol Infect Dis, 2011,70 : 380 - 386.

二级参考文献20

  • 1黄金竹,母连军.碳青霉烯类抗生素的研究概况[J].国外医药(抗生素分册),2007,28(4):145-154. 被引量:45
  • 2Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Sixteenth in- formational supplement, 2011 ,M100-S21.
  • 3Jones RN. Microbial etiologies of hospital acquired bacterial pneumonia and ventilator-associated bacterial pneumonia[J]. Clin Infect Dis, 2010, 51 Suppl1:s81-87.
  • 4Liu YM, Chen YS, Toh HS, et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) [J]. Int J Antimierob Agents, 2012,40 Suppl : s11-17.
  • 5Xiao M, Wang Y, Yang QW, et al. Antimicrobial susceptibility of Pseudomonas aeruginosa in China: a review of two multicentre surveillance programmes, and application of revised CLSI susceptibility breakpoints[J]. Int J Antimicrob Agents, 2012,40(5) :445-449.
  • 6Master RN, Clark RB, Karlowsky JA, et al. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009[J]. Int J Antimicrob Agents, 2011,38(4) :291-295.
  • 7Lee NY, Wang CL, Chuang YC, et al. Combination carbapen- em-sulbactam therapy for critically ill patients with multidrug- resistant Acinetobacter baumannii bacteremia: four case re- ports and an in vitro combination synergy study[J]. Pharma- cotherapy, 2007,27 (11) :1506-1511.
  • 8Pongpech P,Amornnopparattanakul S,Panapakdee S,et al. Anti- bacterial activity of carbapenem-based combinations againts multi- drug-resistant Acinetobacter baurnannii [J]. J Med Assoc Thai, 2010,93(2) : 161-171.
  • 9Song JY,Kee SY, Hwang IS, et al. In vitro activities of car- bapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii[J]. J Antimicrob Chemother, 2007,60(2):317-322.
  • 10Kiratisin P,Apisarnthanarak A,Kaewdaeng S,etal. Synergis- tic activities between carbapenems and other antimicrobial a- gents against Acinetobacter baumannil including multidrug-rc- sistant and extensively drug-resistant isolates[J]. Int J Anti- microb Agents,2010,36(3) :243-246.

共引文献111

同被引文献39

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部